Saitsu K., Yamada K., Kawabata K., Torita S., Watanabe A., Ohtomo N. Long-term safety, tolerability, and cognitive effects of standardized Hericium erinaceus aqueous extract in older adults with mild cognitive impairment: A 24-week randomized placebo-controlled phase IIb with 24-week open-label extension. Nutritional Neuroscience. 2024;27(9):3512–3525.
Rationale
Most lion's mane trials run 4–16 weeks — too short to answer the chronic-use safety question that matters for a supplement people take for months. This phase IIb study put safety and tolerability first, with validated cognitive batteries (ADAS-Cog, RBANS) as efficacy measures.
Methods
A randomized double-blind placebo-controlled phase IIb trial: 88 participants aged 60–83 with MCI by Petersen criteria. Phase one — 24 weeks of standardized hot-water H. erinaceus extract 3 g/day versus placebo; phase two — a further 24 weeks open-label where all participants received the active extract (64 continued). Safety was the primary endpoint; cognition was tracked on ADAS-Cog and RBANS.
Results
Safety: no drug-related serious adverse events over either the 24-week blinded phase or the full 48-week observation; total adverse-event rates were essentially identical between arms (59% extract vs 57% placebo). Efficacy: in the blinded phase the extract group showed a small but statistically significant advantage on ADAS-Cog and RBANS.
Conclusions
Six months of daily standardized extract appears genuinely safe in an elderly MCI population — the strongest safety dataset for the species — and produced a modest but real cognitive signal on modern validated batteries.
Worth noting
This is the most rigorous lion's mane human study to date: phase IIb, modern scales (the exact instruments earlier reviewers asked for), a 48-week horizon, and a safety-first primary endpoint it cleanly passed. The honest caveat remains: "small but significant" effects on ADAS-Cog/RBANS are encouraging, not disease-modifying proof; MCI progression is slow and heterogeneous.